We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 22, 2021

Safety and Effectiveness of Weekly Combination Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab for Newly Diagnosed Multiple Myeloma

JAMA Oncology

 

Additional Info

JAMA Oncology
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial
JAMA Oncol 2021 Apr 15;[EPub Ahead of Print], O Landgren, M Hultcrantz, B Diamond, AM Lesokhin, S Mailankody, H Hassoun, C Tan, UA Shah, SX Lu, M Salcedo, K Werner, J Rispoli, J Caple, A Sams, D Verducci, K Jones, I Concepcion, A Ciardello, A Chansakul, J Schlossman, E Tavitian, T Shekarkhand, A Harrison, C Piacentini, EH Rustad, V Yellapantula, K Maclaughlan, F Maura, HJ Landau, M Scordo, DJ Chung, G Shah, OB Lahoud, K Thoren, K Murata, L Ramanathan, ME Arcila, C Ho, M Roshal, A Dogan, A Derkach, SA Giralt, N Korde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading